RESULTS
A total of 17283 patients underwent isolated valve intervention during the study period; of these 1376 (7.9%) had clinical and laboratory findings for MetS. Overall population baseline characteristics and post-operative results for those with or without MetS are reported inSupplementary Table 1 and 2 .
The MVS, SVAR and TAVR cohort accounted for the 39.4%, 48.2% and 12.3% of the whole cohort respectively.
Mitral \(\pm\ \)tricuspid valve surgical cohort
Baseline patients’ characteristic and post-operative results for MVS cohort (n=6815) are given in Table 1.
Patients in the MetS group (n=309), when compared to the no-MetS (n=6506) were older (70.8 (8.3) y/o vs. 65.2 (12.7) y/o, p<0.001), with higher proportion of female patient (57% vs. 49.1%, p=0.008), and with generally greater burdens of clinical comorbidities.
Notably, there was no difference in terms of proportion of patients operated with minimally invasive approach among the two groups (52.8% vs. 48.9%, p=0.20). Cardiopulmonary bypass (88 (46) min vs. 81 (43.5) min, p=0.37) was longer in the MetS group.
The presence of MetS was associated to increased number of patients who received at least two units of RBC (42.7% vs. 26.9%, p<0.001) and post-operative renal failure (20.1% vs. 5.9%, p<0.001). Both mechanical ventilation time (8 (7) hours vs. 7 (6) hours, p=0.02) and intensive care unit (ICU) stays (2 (2) days vs. 2 (1) days, p<0.001)) were longer in the MetS group.
Overall post-operative LOS (11 (9) days vs. 10 (6) days, p<0.001) were longer in the MetS group (Figure 1 A/B/C ). In-hospital mortality rate was significantly higher in the MetS group (6.5% vs. 2%, p<0.001).